SOULMATE:不适合手术或消融的孤立性结直肠癌肝转移肝移植对比最佳既定治疗的随机对照多中心瑞典研究
SOULMATE研究是一项随机对照多中心试验,评估对不适合切除或消融的结直肠癌肝转移患者,采用主要来自扩展标准供体的肝移植联合最佳既定治疗是否较单用最佳既定治疗提高总生存。研究结果有望在随机设置下验证既往非随机研究的阳性结果,扩展标准供体的使用使结果更具全球可推广性。
要点
- 约20%的结直肠癌肝转移患者适合手术,不可切除者标准治疗为姑息性肿瘤治疗,5年生存率不足10%。
- 非随机研究提示肝移植可能为因肿瘤负荷大、未来残肝小或术后早期复发等原因不适合手术或消融的选定患者提供选择。
- SOULMATE研究将患者随机分配至肝移植联合最佳既定治疗组或单用最佳既定治疗组,比较总生存。
核心结论
- SOULMATE研究有可能在随机设置下确认既往研究的阳性结果,扩展标准供体的使用使结果在全球范围内可推广。
研究设计与样本
- SOULMATE研究是一项随机对照多中心试验,评估主要来自扩展标准供体的肝移植联合最佳既定治疗对比单用最佳既定治疗,能否提高不适合切除或消融的结直肠癌肝转移患者的总生存。
- 患者被随机分配至肝移植联合最佳既定治疗组或单用最佳既定治疗组。
- 试验注册号NCT04161092,注册日期2019年11月13日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Around one fourth of patients with colorectal cancer present themselves with distant metastases at the time of diagnosis, and one additional one fifth of the patients will develop distant metastases during the disease, most commonly in the liver. Surgical treatment such as liver resection or ablation, often combined with chemotherapy and targeted therapy, is the only treatment option with curative potential, but only about 20% of the patients with liver metastases are candidates for surgical intervention. Standard treatment for unresectable patients is palliative oncological therapy; however, less than 10% of these patients will achieve a 5-year survival. Non-randomized studies indicate that liver transplantation could be an option for selected patients with colorectal liver metastases (CRLM), which are not suitable for operation or ablation due to surgical technical reasons such as massive tumor burden and small future liver remnant, or oncological reasons, for example, early relapse after liver surgery. Since there is a shortage of donated liver grafts, it is important to select the patient group that benefit most from the treatment. Although some studies present positive results from liver transplantation of CRLM, the results must be validated in a randomized controlled trial before this new indication for liver transplantation can be introduced as a clinical routine. METHODS: The SOULMATE study is a randomized study evaluating if liver transplantation with liver grafts, primarily from extended criteria donors, increases overall survival in patients with CRLM, not suitable for resection or ablation, in comparison with best established treatment. Patients will be randomized to liver transplantation (LT)+ best established treatment (BET) or to best established treatment only. In the SOULMATE trial, we will evaluate the use of livers from extended criteria donors to decrease the risk of prolonging waiting time for patients on the waiting list for LT. DISCUSSION: The SOULMATE study has the possibility to confirm the positive results of previous studies in a randomized setting. The use of extended criteria donors will make the results transferable globally, as most countries are struggling with organ shortage. TRIAL REGISTRATION: Clinical Trial number: NCT04161092 registered 13 November 2019.
引用
- Reivell V, Hagman H, Haux J, et al. SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatment-a randomized controlled multicenter trial. Trials. 2022. PMID: 36180944. doi:10.1186/s13063-022-06778-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。